Vaxxinity (VAXX) Stock Price, News & Analysis

Company Overview

Vaxxinity Inc. is a biotechnology company focused on developing vaccines and immunotherapies for chronic diseases, including neurodegenerative conditions. The company’s approach is designed to stimulate the body’s immune system to target disease-related proteins or pathways, with the goal of addressing underlying disease biology rather than treating symptoms alone.

Vaxxinity’s research and development pipeline has included UB-311, an investigational vaccine targeting amyloid beta for Alzheimer’s disease, and UB-312, an investigational vaccine designed to target abnormal alpha-synuclein associated with Parkinson’s disease and other synucleinopathies. The company has also pursued programs in other chronic conditions, including migraine and metabolic or endocrine disorders. These products remain investigational and are subject to clinical testing and regulatory review.

The company was formerly known as United Neuroscience and adopted the Vaxxinity name as it broadened its focus on immune-based medicines. Vaxxinity is headquartered in the United States and has conducted development activities through international clinical and research collaborations. Mei Mei Hu, a co-founder of the company, has served as its chief executive officer.

Key Stats

• Today's Range: $0.02 to $0.03
• 50-Day Range: $0.00 to $0.06
• 52-Week Range: $0.00 to $0.20
• Volume: 489 shs
• Average Volume: 13,487 shs
• Market Capitalization: $3.42 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Vaxxinity Stock Analysis - MarketRank™

Vaxxinity scored higher than 10% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Vaxxinity.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Vaxxinity is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Vaxxinity is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

0.37% of the float of Vaxxinity has been sold short.

Short Interest Ratio / Days to Cover

Vaxxinity has a short interest ratio ("days to cover") of 24.49, which indicates bearish sentiment.

Change versus previous month

Short interest in Vaxxinity has recently decreased by 0.24%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Vaxxinity does not currently pay a dividend.

Dividend Growth

Vaxxinity does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: N/A

News Sentiment

Vaxxinity has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Vaxxinity this week, compared to 0 articles on an average week.

MarketBeat Follows

1 people have added Vaxxinity to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Vaxxinity insiders have not sold or bought any company stock.

Percentage Held by Insiders

64.06% of the stock of Vaxxinity is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

82.95% of the stock of Vaxxinity is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 3/27/2023
• Today: 10/28/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:VAXX
• Previous Symbol: NASDAQ:VAXX
• CIK: 1851657
• Web: www.vaxxinity.com
• Phone: 254-244-5739
• Fax: N/A
• Employees: 90
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 126,748,000
• Free Float: 45,553,000
• Market Cap: $3.42 million
• Optionable: Not Optionable
• Beta: -74.42